General evaluation of pipotiazine palmitate (19.552 R.P.) in hospitalized schizophrenic patients.
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007902:Length of Stay; D008297:Male; D008728:Methotrimeprazine / Q000627:therapeutic use; D008875:Middle Aged; D010169:Palmitic Acids / Q000009:adverse effects / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D014150:Antipsychotic Agents; D010169:Palmitic Acids; D010880:Piperidines; D013449:Sulfonamides; D008728:Methotrimeprazine